Amicus Therapeutics
FOLD, today announced preliminary results from an ongoing, open-label
Phase 2 drug-drug interaction study to evaluate the safety and
pharmacokinetic effects of two doses of migalastat HCl (150 mg and 450
mg) co-administered with ERT (agalsidase beta or agalsidase alfa) in up to 24
males diagnosed with Fabry disease.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in